Boehringer Ingelheim
pharmaceutical company focused on innovative therapies for diseases w/o treatment option
Based in DC
AI Overview
With $1.7M in lobbying spend across 25 quarterly filings, Boehringer Ingelheim is a significant lobbying presence. They deploy 12 individual lobbyists Their lobbying covers 3 issue areas. Active from 2020 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $90K |
| 2021 | $360K |
| 2022 | $390K |
| 2023 | $290K |
| 2024 | $280K |
| 2025 | $280K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Boehringer Ingelheim disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Budget/Appropriations
Prescription drug access and affordability, FDA user fee reauthorization
Medicaid value based payment proposed rule
government funding
H.R. 8337 - Continuing Appropriations Act of 2021
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.